CATAPRES-TTS-1 (clonidine transdermal system) by Lavipharm is adrenergic alpha2-agonists [moa]. Approved for central alpha-2 adrenergic agonist [epc]. First approved in 1984.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
CATAPRES-TTS-1 is a transdermal clonidine system approved in 1984 for hypertension management. It works as a central alpha-2 adrenergic agonist, reducing sympathetic nervous system activity to lower blood pressure. The patch formulation provides continuous drug delivery over several days.
Product is in mature LOE-approaching phase with limited commercial growth opportunity; teams are likely focused on defending market share against 30% competitive pressure rather than expansion.
Adrenergic alpha2-Agonists
Central alpha-2 Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings reflect the mature, stable nature of this established product with minimal hiring velocity. Positions on the CATAPRES-TTS-1 team typically involve defensive market strategies and maintaining existing customer relationships rather than growth initiatives.
Worked on CATAPRES-TTS-1 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo